


中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际  
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库



CHINESE JOURNAL OF NEW DRUGS

ISSN 1003-3734  
CN 11-2850/R  
CODEN ZXZHA6

# 中国新药杂志



4  
2019  
Vol.28 | No.4

意大利创新药物条件准入协议政策分析及对我国的启示  
活性炭在注射剂生产中的潜在风险分析  
以细胞表面标志物为研究指标的光致敏体外评价方法  
中药miRNA研究进展  
经PCI治疗的冠心病患者服用氯吡格雷后血小板反应性与基因多态性关系  
白及有效部位中militarine在模式生物斑马鱼中的代谢研究

www.newdrug.cn

ISSN 1003-3734



国家药品监督管理局主管



## •新药述评与论坛•

- 385 意大利创新药物条件准入协议政策分析及对我国的启示.....魏靖哲, 蒋蓉, 孙圆圆, 等  
390 共同审评审批制度下药用辅料质量监管的思考.....邹宜誼, 陈云, 邵蓉, 等  
395 杂质化合物的可专利性问题判断及分析.....王卫彬, 薛琦, 黄璐  
400 新型治疗青光眼药物netarsudil.....闫荟羽, 史吉平, 毛丽超, 等

## •新药注册与审评技术•

- 404 活性炭在注射剂生产中的潜在风险分析.....罗俊永, 杨文智, 张晓攀, 等

## •重大新药创制专项巡礼•

- 408 以细胞表面标志物为研究指标的光致敏体外评价方法.....赵华琛, 刘丽, 李波  
418 ROR $\gamma$ t在感染后咳嗽大鼠肺组织中的表达及黄芩射干汤对其干预作用.....张颖, 王晓月, 温雯, 等  
423 加校正因子自身对照法同时测定富马酸替诺福韦二吡呋酯13个已知杂质.....梁静, 黄俊, 徐登, 等

## •综述•

- 432 中药miRNA研究进展.....王颖芳, 陈艳琳, 王文娟  
437 右美托咪定用于术后急性疼痛的临床研究进展.....耿志宇, 王东信  
442 PROTACs靶向蛋白质降解技术及其在合理药物设计中的应用.....梁倩倩, 曹亚权, 杨鹏, 等

## •临床研究•

- 451 经PCI治疗的冠心病患者服用氯吡格雷后血小板反应性与基因多态性关系.....张正信, 陈竹, 代颜, 等  
458  $\omega$ -3鱼油脂肪乳肠外营养治疗对老年重型颅脑损伤患者预后影响.....孙瑾, 田新华, 黄延林, 等  
463 内镜下喷洒并口服康复新液治疗反流性食管炎168例.....李海峰, 崔传耀

## •实验研究•

- 467 白及有效部位中militarine在模式生物斑马鱼中的代谢研究.....王昌权, 夏涛, 陈浩, 等  
473 经典名方芍药甘草汤UPLC指纹图谱的建立.....柴瑞平, 路娟, 俞月, 等  
479 乌参醒脑方对6-羟基多巴胺诱导帕金森病大鼠的改善作用.....黄亿健, 余江锋, 罗展远, 等  
485 雷公藤红素长循环脂质体的制备和体外性质初步研究.....陈欣妍, 李歆, 王皓南, 等  
492 5-氨基水杨酸结肠定位缓释胶囊的制备及释放度研究.....钟应淮, 刘雪梅, 莫传丽, 等

## •药物安全与合理应用•

- 501 亚胺培南西司他丁钠使用管理监测及合理性分析.....应颖秋, 张哲浩, 杨毅恒, 等  
505 基于BCPNN法的阿格列汀药物警戒信号的挖掘.....施雯慧, 巴磊, 许豪勤

- 385 Analysis of the managed entry agreements policy on innovative drugs of Italy and its enlightenment to China  
WEI Jing-zhe, JIANG Rong, SUN Yuan-yuan, *et al*
- 390 Considerations of the regulation of pharmaceutical excipients' quality under China's joint review system  
ZOU Yi-xuan, CHEN Yun, SHAO Rong, *et al*
- 395 Judgement and analysis of patentability of impurity compounds  
WANG Wei-bin, XUE Qi, HUANG Lu
- 400 A new drug for the treatment of glaucoma: netarsudil  
YAN Hui-yu, SHI Ji-ping, MAO Li-chao, *et al*
- 404 Potential risk analysis of application of activated charcoal in injection manufacture  
LUO Jun-yong, YANG Wen-zhi, ZHANG Xiao-pan, *et al*
- 408 Establishment of *in vitro* photosensitization evaluation method using cell surface markers as evaluation index  
ZHAO Hua-chen, LIU Li, LI Bo
- 418 RORyt expression in the pulmonary tissue of post infection coughing rats and the inhibitory effects of Huangqin shegan decoction  
ZHANG Ying, WANG Xiao-yue, WEN Wen, *et al*
- 423 Assay of related substances in tenofovir disoproxil fumarate bulk drug by self-contrast method with correction factor  
LIANG Jing, HUANG Jun, XU Deng, *et al*
- 432 Research progress of miRNAs in traditional Chinese medicines  
WANG Ying-fang, CHEN Yan-lin, WANG Wen-juan
- 437 Clinical research progress of dexmedetomidine for acute postoperative pain  
GENG Zhi-yu, WANG Dong-xin
- 442 PROTACs-induced protein degradation and its application in drug design  
LIANG Qian-qian, CAO Ya-quan, YANG Peng, *et al*
- 451 Relationship between gene polymorphism and platelet reactivity in patients with coronary heart disease treated with clopidogrel post PCI  
ZHANG Zheng-ji, CHEN Zhu, DAI Yan, *et al*
- 458 Effect of omega-3 fish oil fat emulsion parenteral nutrition on prognostic of geriatric patients with severe craniocerebral injury  
SUN Jin, TIAN Xin-hua, HUANG Yan-lin, *et al*
- 463 Clinical study on effect of orally kangfuxin liquid combined with spraying it through gastrocope in treating 168 cases of reflux esophagitis  
LI Hai-feng, CUI Chuan-yao
- 467 Metabolism of militarine component of the effective fractions of *Bletilla striata* in zebrafish  
WANG Chang-quan, XIA Tao, CHEN Hao, *et al*
- 473 Establishment of UPLC fingerprint of Shaoyao gancao decoction: a classical herbal formula  
CHAI Rui-ping, LU Juan, YU Yue, *et al*
- 479 The therapeutic effect of Wushen-Xingnao Fang on 6-hydroxydopamine-induced Parkinson's disease  
HUANG Yi-jian, YU Jiang-feng, LUO Zhan-yuan, *et al*
- 485 Preparation and *in vitro* characterization of celastrol-loaded long circulating liposomes  
CHEN Xin-yan, LI Xin, WANG Hao-nan, *et al*
- 492 Preparation and drug release *in vitro* of 5-amino salicylic acid colon specific sustained release capsules  
ZHONG Ying-huai, LIU Xue-mei, MO Chuan-li, *et al*
- 501 Antimicrobial stewardship monitoring and rationality analysis of imipenem and cilastatin sodium  
YING Ying-qiu, ZHANG Zhe-hao, YANG Yi-heng, *et al*
- 505 Pharmacovigilance signal detection of alogliptin based on Bayesian confidence propagation neural network Method  
SHI Wen-hui, BA Lei, XU Hao-qin

**Directed by:** National Medical Products Administration  
**Sponsored by:** China Medical Science Press  
China National Pharmaceutical Group Corp.  
Chinese Pharmaceutical Association  
**Editor-in-Chief:** SANG Guo-wei  
**Board Chairman:** SHI Sheng-yi  
**Edited by:** Editorial Board of Chinese Journal of New Drugs  
**Published by:** Chinese Journal of New Drugs Co., Ltd.  
**Address:** Room 317, No.3 Chengming Building, No.2 Xizhimen South Street, Xicheng District, Beijing 100035, China  
**Tel:** (010)52722697 / 52722651 / 52723707

**Website:** <http://www.newdrug.cn>  
**E-mail:** [bianjibu@newdrug.cn](mailto:bianjibu@newdrug.cn)  
**Printer:** Beijing Kexin Printing Co., Ltd.  
**Domestic Distribution:** Beijing Post Offices  
**Overseas Distribution:** China International Book Trading Corp. (P.O.Box 399 Beijing, China)  
**Domestic Subscription:** Local Post Offices  
**Periodical Registration:** ISSN 1003-3734 CN 11-2850/R  
**Publication Date:** February 28, 2019  
**Copyright:** 2019 by Chinese Journal of New Drugs Co., Ltd.





**科伦药业**  
KELUN PHARMACEUTICAL



**多悦™**

# 1000ml全合一肠外营养液

Precision Nutrition Precision Goal

——满足大多数患者肠外营养治疗需求

## 脂肪乳(10%)/氨基酸(15)/葡萄糖(20%)注射液

1000ml

批准文号:国药准字H20183272

1500ml

批准文号:国药准字H20183271



### 简明处方:

#### 【成分】

本品的包装分为内袋与外袋,在内袋与外袋之间放置吸氧剂。内袋由两条可剥离封条分隔成三个独立的腔室,分别装有葡萄糖(20%),复方氨基酸(5.5%, 15AA),脂肪乳注射液(10%)。

#### 【适应症】

当口服或肠内摄取营养不能、不足或禁忌时用于肠道外营养。

#### 【用法用量】

中央或外周静脉输注。仅用于2岁以上的儿童和成人。根据患者的代谢需求,能量消耗和临床状况来确定剂量。

#### 【不良反应】

长期肠外营养治疗期间,有短暂的碱性磷酸酶、转氨酶和胆红素水平增高的报告,一旦剂量减低,这些参数将恢复正常,肝肿大和黄疸罕见。输注脂肪乳,儿童血小板减少症罕见。详见说明书。

#### 【禁忌】

本品在下列情况下禁用:已知的对任何成分的过敏;失代偿的心功能不全、肺水肿和水肿;严重肝功能不全;严重高脂血症;未经血液透析和/或血液透析滤过治疗的肾功能不全(缺乏相关数据);不足2岁的儿童、新生儿;病理学高钠、钾、镁、钙和/或磷的血浆浓度;严重的高血糖症;先天性氨基酸代谢异常。

#### 【有效期】

18个月



生产企业:四川科伦药业股份有限公司  
生产地址:四川省成都市新都卫星城工业开发区南二路  
邮政编码:610500  
电话号码:(028)86130259  
传真号码:(028)86139152

【本广告仅供医学药学专业人士阅读】  
广告审查批准文号 川药广审(文)第2018120311号

国内定价:50.00元 国内统一刊号CN11-2850/R 邮发代号82-488 国外代号M4240